Clinical trials: Cabozantinib
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men…
- Trial name
- CONTACT-02 (NCT04446117)
- Testing
- Cabozantinib, Atezolizumab, Abiraterone Acetate
- Where
- 280 sites in United States, Argentina and 25 more
- Volunteers
- 575 people
- Sponsor
- Exelixis
Advanced Renal Cell Carcinoma
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world…
- Trial name
- CaboCombo (NCT05361434)
- Where
- 66 sites in Belgium, France and 6 more
- Volunteers
- 311 people
- Sponsor
- Ipsen
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
- Trial name
- NCT04586231
- Testing
- Belzutifan, Lenvatinib, Cabozantinib
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 747 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients…
- Trial name
- CONTACT-01 (NCT04471428)
- Testing
- Cabozantinib, Atezolizumab, Docetaxel
- Where
- 92 sites in United States, Australia and 13 more
- Volunteers
- 366 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo.
- Trial name
- COSMIC-313 (NCT03937219)
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 159 sites in United States, Argentina and 23 more
- Volunteers
- 855 people
- Sponsor
- Exelixis
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 191 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Advanced Renal Cell Carcinoma
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate the efficacy of cabozantinib measured by Independent Radiology Committee (IRC)-assessed objective response rate (ORR) in Japanese participants with advanced renal cell carcinoma (RCC) that…
- Trial name
- NCT03339219
- Testing
- Cabozantinib
- Where
- 19 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Takeda
Advanced Hepatocellular Carcinoma
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic…
- Trial name
- NCT05797805
- Testing
- Tegavivint, Lenvatinib, Cabozantinib
- Where
- 8 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Iterion Therapeutics
Solid Tumors, Cancer
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese…
- Conditions
- Solid Tumors, Cancer, NSCLC
- Trial name
- NCT01553656
- Testing
- cabozantinib capsules, cabozantinib tablets
- Where
- 2 sites in Japan
- Volunteers
- 85 people
- Sponsor
- Exelixis
Hepatocellular Cancer
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma.
- Trial name
- NCT05100082
- Testing
- Cabozantinib
- Where
- Japan
- Volunteers
- 263 people
- Sponsor
- Takeda
Renal Cell Carcinoma
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.
- Trial name
- PIVOT IO 011 (NCT04540705)
- Testing
- Nivolumab, Axitinib, Cabozantinib
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Advanced Renal Cell Carcinoma
A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK
Clinical experience with cabozantinib is limited in the UK and Ireland and there is anecdotal evidence of there being variability between clinicians in terms of where cabozantinib is used in the treatment pathway.
- Trial name
- NCT03696407
- Where
- 6 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Ipsen
Renal Cell Carcinoma
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has…
- Trial name
- METEOR (NCT01865747)
- Testing
- Cabozantinib tablets, Everolimus (Afinitor) tablets
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 658 people
- Sponsor
- Exelixis